A new antibiotic named Sorfequiline has demonstrated promising results in clinical trials as a potent treatment for Tuberculosis (TB). The drug is shown to be stronger than existing treatments and could potentially be effective against drug-resistant strains of the deadly bacteria. If approved, a Sorfequiline-based regimen could simplify and streamline the initial treatment process for newly diagnosed patients. This medical advancement arrives at a critical time when global progress toward eliminating TB is threatened by aid cuts.
November 15, 2025 theguardian.com